Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Gilberg

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
ACS Omega|August 29, 2019
Promiscuous Ligands from Experimentally Determined Structures, Binding Conformations, and Protein Family-Dependent Interaction HotspotsErik Gilberg, Michael Gütschow, Jürgen Bajorath
F1000Research|October 25, 2017
Towards a systematic assessment of assay interference: Identification of extensively tested compounds with high assay promiscuityErik Gilberg, Dagmar Stumpfe, Jürgen Bajorath
Future Science OA|March 24, 2018
Series of screening compounds with high hit rates for the exploration of multi-target activities and assay interferenceDagmar Stumpfe, Erik Gilberg, Jürgen Bajorath
Journal of Medicinal Chemistry|January 13, 2018
X-ray Structures of Target-Ligand Complexes Containing Compounds with Assay Interference PotentialErik Gilberg, Michael Gütschow, Jürgen Bajorath
ACS Omega|July 20, 2018
X-ray-Structure-Based Identification of Compounds with Activity against Targets from Different Families and Generation of Templates for Multitarget Ligand DesignErik Gilberg, Dagmar Stumpfe, Jürgen Bajorath
Journal of Medicinal Chemistry|November 14, 2018
Machine Learning Distinguishes with High Accuracy between Pan-Assay Interference Compounds That Are Promiscuous or Represent Dark Chemical MatterSwarit Jasial, Erik Gilberg, Thomas Blaschke, et al.
The AAPS Journal|March 8, 2017
Structure-Promiscuity Relationship Puzzles-Extensively Assayed Analogs with Large Differences in Target AnnotationsYe Hu, Swarit Jasial, Erik Gilberg, et al.
Journal of Medicinal Chemistry|November 5, 2016
Highly Promiscuous Small Molecules from Biological Screening Assays Include Many Pan-Assay Interference Compounds but Also Candidates for PolypharmacologyErik Gilberg, Swarit Jasial, Dagmar Stumpfe, et al.
Journal of Medicinal Chemistry|November 16, 2019
How Significant Are Unusual Protein-Ligand Interactions? Insights from Database MiningBernd Kuhn, Erik Gilberg, Robin Taylor, et al.
Bioorganic & Medicinal Chemistry|November 27, 2018
Cathepsin B: Active site mapping with peptidic substrates and inhibitorsJanina Schmitz, Erik Gilberg, Reik Löser, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
ACS Omega|August 29, 2019
Promiscuous Ligands from Experimentally Determined Structures, Binding Conformations, and Protein Family-Dependent Interaction HotspotsErik Gilberg, Michael Gütschow, Jürgen Bajorath
F1000Research|October 25, 2017
Towards a systematic assessment of assay interference: Identification of extensively tested compounds with high assay promiscuityErik Gilberg, Dagmar Stumpfe, Jürgen Bajorath
Future Science OA|March 24, 2018
Series of screening compounds with high hit rates for the exploration of multi-target activities and assay interferenceDagmar Stumpfe, Erik Gilberg, Jürgen Bajorath
Journal of Medicinal Chemistry|January 13, 2018
X-ray Structures of Target-Ligand Complexes Containing Compounds with Assay Interference PotentialErik Gilberg, Michael Gütschow, Jürgen Bajorath
ACS Omega|July 20, 2018
X-ray-Structure-Based Identification of Compounds with Activity against Targets from Different Families and Generation of Templates for Multitarget Ligand DesignErik Gilberg, Dagmar Stumpfe, Jürgen Bajorath
Journal of Medicinal Chemistry|November 14, 2018
Machine Learning Distinguishes with High Accuracy between Pan-Assay Interference Compounds That Are Promiscuous or Represent Dark Chemical MatterSwarit Jasial, Erik Gilberg, Thomas Blaschke, et al.
The AAPS Journal|March 8, 2017
Structure-Promiscuity Relationship Puzzles-Extensively Assayed Analogs with Large Differences in Target AnnotationsYe Hu, Swarit Jasial, Erik Gilberg, et al.
Journal of Medicinal Chemistry|November 5, 2016
Highly Promiscuous Small Molecules from Biological Screening Assays Include Many Pan-Assay Interference Compounds but Also Candidates for PolypharmacologyErik Gilberg, Swarit Jasial, Dagmar Stumpfe, et al.
Journal of Medicinal Chemistry|November 16, 2019
How Significant Are Unusual Protein-Ligand Interactions? Insights from Database MiningBernd Kuhn, Erik Gilberg, Robin Taylor, et al.
Bioorganic & Medicinal Chemistry|November 27, 2018
Cathepsin B: Active site mapping with peptidic substrates and inhibitorsJanina Schmitz, Erik Gilberg, Reik Löser, et al.
Pageof 2